Press Releases Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
14.62 ^USD	+6.10%		+1.46%	+177.95%

May. 27	Certain Pre-Funded Warrants of Stoke Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	CI
May. 27	Certain Common Stock of Stoke Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Encephalopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	May. 21	AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	May. 20	AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	May. 17	BU
Stoke Therapeutics : Corporate Presentation - May 2024	May. 06	PU
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates	May. 06	BU
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer	Apr. 29	BU
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer	Apr. 17	BU
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 04	BU
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering	Mar. 27	BU
Stoke Therapeutics Announces Proposed Public Offering	Mar. 26	BU
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 25	BU
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome	Mar. 25	BU
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies	Feb. 08	AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Jan. 18	AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	Jan. 17	BU
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024	Jan. 08	BU
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	BU
Stoke Therapeutics Presents Data from Multiple Studies of Children and Adolescents with Dravet Syndrome at the American Epilepsy Society 2023 Annual Meeting	Dec. 04	AQ
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting	Dec. 01	BU
Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting	Nov. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Press Releases

Filters